Jong Wook Kim
University of California San Diego · 39 works · 2,436 citations · h-index 13
Top works
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
- Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
- A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
- KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
- Targeting TBK1 to overcome resistance to cancer immunotherapy
- Characterizing genomic alterations in cancer by complementary functional associations
- An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer
- Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
- Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States
- DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets
- STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells
- Modelling bistable tumour population dynamics to design effective treatment strategies
- The multikinase inhibitor RXDX-105 is effective against neuroblastomain vitroandin vivo
- Author response: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
- Author response: An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer
- Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors
- Supplemental Figure Legends from Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations
- MB-103DiSCoVERing INNOVATIVE THERAPIES: COMBINING GENETICALLY ACCURATE DISEASE MODELS OF MEDULLOBLASTOMA WITH ADVANCED IN SILICO ANALYSIS TO IDENTIFY NOVEL THERAPEUTIC TARGETS
- Supplementary Figure 3 from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets